Opus Genetics (IRD) Cash from Investing Activities Growth (1y) (2011 - 2021)
Powered by 
Analysis
Opus Genetics (IRD) Cash from Investing Activities Growth (1y) (2011 - 2021) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 26.37% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -89.24% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | -118.55% |
| Dec 31, 2020 | 536.26% |
| Dec 31, 2019 | -106.18% |
| Sep 30, 2019 | -18.13% |
| Jun 30, 2019 | -7.86% |
| Mar 31, 2019 | -296.67% |
| Dec 31, 2018 | 165.30% |
| Sep 30, 2018 | 22.29% |
| Jun 30, 2018 | 132.44% |
| Mar 31, 2018 | 321.98% |
| Dec 31, 2017 | -165.45% |
| Sep 30, 2017 | 257.18% |
| Jun 30, 2017 | -504.38% |
| Mar 31, 2017 | 192.69% |
| Dec 31, 2016 | 209.41% |
| Sep 30, 2016 | -127.39% |
| Jun 30, 2016 | -6.01% |
| Mar 31, 2016 | -118.09% |
| Dec 31, 2015 | -91.50% |
| Sep 30, 2015 | 133.90% |